1 / 12

Statistics in Drug Development

Statistics in Drug Development. Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration. * The views expressed here are those of the author and not necessarily those of the FDA. . Various Indications for Drugs. For example: Headache/Pain medicine, psychiatric drugs,

lalo
Télécharger la présentation

Statistics in Drug Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the author and not necessarily those of the FDA.

  2. Various Indications for Drugs For example: Headache/Pain medicine, psychiatric drugs, AIDS treatments, Cancer drugs, etc. Details about the design and goal of a study depends on the indication of the drug (how the drug will be used).

  3. Goal of New Drug Development Develop a safe and effective drug.

  4. Phases of Drug Development Pre-clinical - Animal testing Phase 1 - Dose ranging (toxicity) Phase 2 - Use of the drug in a small number of studies (efficacy screening) Phase 3 - Comparative study with a placebo or an active drug (usually the standard therapy) Phase 4 - Post-marketing studies

  5. Comparative Phase 3 Trials Aspects of a quality comparative study - Randomization (patients are randomly divided into groups) - Stratification - Double-Blind (eliminate a placebo-effect and diagnosis bias) - Control

  6. Endpoints (Variables of Interest) Examples of Oncology Endpoints: Survival Time Tumor response (binary or ordinal variable) Time to tumor progression Quality of Life

  7. Hypotheses H0: experimental drug and the standard drug (or placebo) have the same effectiveness H1: experimental drug and the standard drug (or placebo) have different effectiveness Alternative hypotheses are two-sided. Hypotheses are formally for those patients in the study. One or more endpoints may tested.

  8. Potential Errors Type I error: Rejecting H0 when H0 is true (false positive rate) Type II error: Failing to reject H0 when H1 is true ( or for the drug company the type II error of interest is failing to conclude the drug is effective when it is effective) An overall probability of a type I error is maintained at 0.05 for the primary efficacy analysis. If more than one endpoint is involved in the primary efficacy analysis, individual type I errors are adjusted for the total number of comparisons.

  9. Sample Size Determination Aspects considered for the sample size calculation: - A primary method of analysis is selected. - Desired Type II error probability at a clinically meaningful effectiveness alternative. - Accrual Period - Follow-up time - Fraction of dropouts

  10. Analysis Populations Intent-to-treat Population: All patients as randomized Evaluable Population: All patients who received study therapy that have measurements for the primary efficacy endpoint and comply with the protocol.

  11. Statistical Conclusions Patients in the study are volunteers - not randomly selected from some group. Formally, any conclusions of statistical significance is good only for that set of patients in the study.

  12. Other Issues - Formal Definitions of Endpoints - Missing Data (common in quality of life measurements) - Crossover to other therapies - Censoring - Robustness with respect to the method of analysis chosen - Interim Efficacy Analyses

More Related